Attovia (ATTO) CSO Petter Veiby Receives Award

What Happened
Petter Veiby, Chief Scientific Officer of Attovia Therapeutics (ATTO), received a grant of 140,000 derivative securities on August 4, 2026 (reported acquisition price $0.00). The filing treats the award as options; no cash was paid in connection with this grant. This is an equity grant (award), not a sale.

Key Details

• Transaction date: August 4, 2026; Form 4 filed August 6, 2026 (filed within the standard reporting window).
• Amount: 140,000 derivative securities (reported as acquisition A) at $0.00.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Vesting (footnote): 25% of the options vest on August 4, 2027; remaining options vest in equal monthly installments over the following 36 months, subject to continued service.
• No sale or exercise reported; this is a time‑based award subject to future vesting.

Context
This is a standard equity incentive award intended to align management with shareholder interests; it does not represent an immediate purchase or sale of stock. The options will only convert to exercisable/owned shares as they vest per the schedule above.